News and Media
News and Media
Valerio Therapeutics announces binding offer for the proposed acquisition of Etherna Immunotherapies, creating a global leader in targeted RNA medicines
July 1, 2026
Valerio Therapeutics Appoints Gilles Besin as Chief Executive Officer and Announces Results of its Annual General Meeting
June 16, 2026
Valerio Therapeutics announces binding term-sheet for collaboration and exclusive license with seed-stage biotech company
May 18, 2026
Valerio Therapeutics announces the launch of InVimmune, a new company dedicated to developing differentiated in vivo cell therapy approaches
May 4, 2026
Valerio Therapeutics publishes its 2025 annual results and annual financial report, and confirms the strategic transformation of its operating model
April 28, 2026
Valerio Therapeutics announces the appointment of Eric Vivier as observer to its Board of Directors
December 15, 2025
COMPLETION OF THE MERGER BETWEEN VALERIO THERAPEUTICS AND ITS SUBSIDIARY VALOUR BIO
December 12, 2025
Valerio Therapeutics announces an addition in the composition of its Board of Directors
November 26, 2025
Proposed merger between Valerio Therapeutics and its subsidiary Valour Bio
October 31, 2025
Publication of the Half Yearl Report 2025
October 29, 2025
Valerio Therapeutics announces the completion of a capital increase with cancellation of preferential subscription rights
October 15, 2025
Transactions on the share capital of Valerio Therapeutics to restructure part of its liabilities
July 22, 2025
Resumption of trading from July 10, 2025
July 10, 2025
Publication of the Annual Report 2024
July 9, 2025
Temporary suspension of trading effective 17 June 2025
July 9, 2025
[wd_hustle id=”2″ type=”embedded”/]
